Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693374 | 0.94 | TRPA1 (0.64) | TRPA1TRPV1KCNH2TRPM8MALT1 | |
| SCHEMBL31348096 | 0.83 | HSD11B1 (0.54) | TRPA1CNR2TRPV1MALT1 | |
| SCHEMBL5239263 | 0.82 | CNR2 (0.39) | TRPA1CNR2TRPV1MALT1 | |
| SCHEMBL14257166 | 0.81 | TRPA1 (0.62) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL13930766 | 0.81 | TRPA1 (0.62) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL2812388 | 0.80 | RBP4 (0.49) | MALT1 | |
| SCHEMBL28203428 | 0.80 | HSD11B1 (0.54) | TRPA1CNR2TRPV1MALT1 | |
| SCHEMBL26669421 | 0.79 | MEN1 (0.74) | TRPA1TRPV1KCNH2TRPM8 | |
| SCHEMBL30980825 | 0.78 | CYP1A2 (0.56) | TRPA1CNR2TRPV1MALT1 | |
| SCHEMBL20139276 | 0.78 | AKR1C3 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | claimed |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | TRPA1 103/4885CNR2 2/4885TRPV1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.